Amgen Statement on Aranesp ‘145 Manuscript’ In the Journal of Clinical Oncology

THOUSAND OAKS, Calif. (May 8, 2008) -- Amgen (NASDAQ:AMGN) issued the following statement on the publication of an Aranesp® (darbepoetin alfa) manuscript in the May 10, 2008, issue of the Journal of Clinical Oncology.

“The Aranesp ‘145 study’, a Phase 3 trial designed to test whether previously untreated patients with extensive-stage small -cell lung cancer receiving platinum-containing chemotherapy benefit from treatment with Aranesp, was previously reported by Amgen when results became available in 2007. The results of this study were provided to regulatory agencies, and presented at a scientific conference and other venues throughout last year.

“Amgen is committed to ensuring physicians and their patients have the most up-to-date information on its medicines, including both positive and negative results from clinical trials.”

SOURCE: Amgen
Amgen, Thousand Oaks
Ashleigh Koss, (805) 313-6151 (media)
Arvind Sood, (805) 447-1060 (investors)
###